Skip to main content
Fig. 6 | Cancer Cell International

Fig. 6

From: IGHG1 upregulation promoted gastric cancer malignancy via AKT/GSK-3β/β-Catenin pathway

Fig. 6

IGHG1 activates β-Catenin through inhibition of its phosphorylation process via enhancement of AKT-GSK-3β phosphorylation. A, B qRT-PCR and Western Blot analysis on the association of IGHG1 expression with β-Catenin in clinical samples of gastric cancer patients; C Western Blot study on protein expression level of β-Catenin, p-β-Catenin, p-GSK-3β, GSK-3β, AKT, p-AKT and IGHG1 in cell groups respectively transfected with IGHG1 shRNA and overexpression vectors; D Western Blot experiment on protein expression level of β-Catenin, p-AKT, AKT and IGHG1 in cell groups transfected with IGHG1 overexpression vector, with or without combination of AKT specific inhibitor, MK2206; E Western Blot experiment on protein expression level of β-Catenin, p-AKT, AKT and IGHG1 in cell groups transfected with IGHG1 specific shRNA, with or without combination of GSK-3β specific inhibitor CHIR-99021

Back to article page